Healthcare Sector Announce Awards, Conference Participation, Partnerships, and Closure of Public Offering - Research Report on

Healthcare Sector Announce Awards, Conference Participation, Partnerships, and
  Closure of Public Offering - Research Report on Regeneron, Alnylam, Galena
                  Biopharma, Amedisys, and Aeterna Zentaris

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, December 3, 2013

NEW YORK, December 3, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Regeneron
Pharmaceuticals, Inc. (NASDAQ: REGN), Alnylam Pharmaceuticals, Inc. (NASDAQ:
ALNY), Galena Biopharma, Inc. (NASDAQ: GALE), Amedisys Inc. (NASDAQ: AMED),
and Aeterna Zentaris Inc. (USA) (NASDAQ: AEZS). Today's readers may access
these reports free of charge - including full price targets, industry analysis
and analyst ratings - via the links below.

Regeneron Pharmaceuticals, Inc. Research Report

On November 25, 2013, Regeneron Pharmaceuticals, Inc. (Regeneron) and Sanofi
jointly announced that the Phase 2a study of dupilumab in asthma was named
"Clinical Advance of the Year" by Scrip Intelligence at the 9th annual Scrip
Awards. According to the Company, Dupilumab is a fully-human monoclonal
antibody, developed by Regeneron in association with Sanofi for the treatment
of asthma, atopic dermatitis, and nasal polyposis. George D. Yancopoulos,
M.D., Ph. D., Chief Scientific Officer of Regeneron and President of Regeneron
Laboratories, said, "We appreciate the recognition by Scrip that dupilumab is
one of the most exciting emerging clinical candidates in the industry. We feel
that this award is additional validation of the overall depth and productivity
of our R&D team and the powerful VelociSuite® technologies they employ, which
have delivered dupilumab and several other investigational therapeutic
opportunities." The Full Research Report on Regeneron Pharmaceuticals, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/8ea7_REGN

--

Alnylam Pharmaceuticals, Inc. Research Report

ON November 25, 2013, Alnylam Pharmaceuticals, Inc. (Alnylam) announced that
its management will present a Company overview at the 25th Annual Piper
Jaffray Healthcare Conference on Wednesday, December 4, 2013 at 11:00 a.m. ET
at The New York Palace in New York City. Alnylam stated that it will also make
a presentation at the 2013 Deutsche Bank BioFEST on Monday, December 2, 2013
at 7:50 a.m. ET at the Four Seasons Hotel in Boston. According to the Company,
a live audio webcast of both the presentations will be available on the News &
Investors section of Alnylam's website. The Full Research Report on Alnylam
Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/5b29_ALNY

--

Galena Biopharma, Inc. Research Report

On November 26, 2013, Galena Biopharma, Inc. (Galena Biopharma) announced that
its President and CEO, Mark J. Ahn, Ph.D., will present a corporate update at
the 25th Annual Piper Jaffray Healthcare Conference. According to the Company,
the presentation will take place on Tuesday, December 3, 2013 at 8:10 a.m. ET
at The New York Palace Hotel in New York, NY. The Company stated that
interested parties can access an webcast of the presentation at the Investors
section of Galena Biopharma's website. The Full Research Report on Galena
Biopharma, Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/cad6_GALE

--

Amedisys Inc. Research Report

On November 22, 2013, Amedisys Inc. (Amedisys) announced that it has teamed up
with Antidote Education Company to offer Continuing Education webinars for
physicians on two increasingly important topics - home health and hospice
care. The Company stated that it's specially designed webinar, "It's Not Easy,
But It's Not That Hard: Discussing Hospice Goals of Care," will deliver
insights into the services available through hospice care as well as advice on
carrying on the crucial, end-of-life conversation with patients and their
families. Additionally, Amedisys informed that its webinar to educate
physicians about the clinical advantages of home health care, "Health Care at
Home" will address eligibility requirements and feature advice about how home
health care can improve patient outcomes, prevent unnecessary hospital
readmissions and lower healthcare spending. The Full Research Report on
Amedisys Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/56b5_AMED

--

Aeterna Zentaris Inc. (USA) Research Report

On November 25, 2013, Aeterna Zentaris Inc. (USA) (Aeterna Zentaris) announced
the closing of its previously announced public offering of 13.1 million units,
generating net proceeds of c.$13.7 million, with each unit consisting of one
common share and one whole warrant to purchase one common share, at a purchase
price of $1.15 per unit. According to the Company, each warrant is exercisable
for a period of five years at an exercise price of $1.60 per share. Aeterna
Zentaris stated that Canaccord Genuity Inc. acted as the sole book-running
manager, and Maxim Group LLC acted as co-manager for the offering and net
proceeds from the same will be used to continue to fund its ongoing drug
development activities, primarily for the advancement of its zoptarelin
doxorubicin (AEZS-108) program, secondly for its macimorelin acetate
(AEZS-130) program, including the preparation of its commercial launch, as
well as for the potential addition of commercialized products to the Company's
pipeline, future negative cash flow, general corporate purposes and working
capital. The Full Research Report on Aeterna Zentaris Inc. (USA) - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/3499_AEZS

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)